Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastasesRE Coleman, HS Rugo, Georgeta Fried et al.|Cancer Research|2017Cited by 2